Co-Authors
This is a "connection" page, showing publications co-authored by VASSILIKI A PAPADIMITRAKOPOULOU and ANNE TSAO.
Connection Strength
2.797
-
The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21.
Score: 0.445
-
Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1789-90.
Score: 0.402
-
The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614.
Score: 0.391
-
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
Score: 0.350
-
Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precis Oncol. 2017 Nov; 1:1-10.
Score: 0.152
-
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647.
Score: 0.142
-
Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer. 2016; 11:21.
Score: 0.137
-
Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.
Score: 0.136
-
Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb; 3(1):53-63.
Score: 0.118
-
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
Score: 0.101
-
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
Score: 0.070
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
Score: 0.062
-
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients?With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep. 2023 Mar; 4(3):100423.
Score: 0.054
-
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
Score: 0.049
-
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2021 Feb; 76(2):155.e25-155.e34.
Score: 0.047
-
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
Score: 0.045
-
Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
Score: 0.045
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.025
-
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
Score: 0.024